RGEDF (Chemical Works of Gedeon Richter) Moat Score: 6/10 (As of Jun. 28, 2026)


RGEDF Chemical Works of Gedeon Richter PLC RGEDF
94 GF Score
Price $39.59
GF Value $36.19
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Chemical Works of Gedeon Richter Moat Score?

Chemical Works of Gedeon Richter RGEDF -1.78% 94 Moat Score is 6 as of Jun. 28, 2026. GuruFocus rates RGEDF with a GF Score™ of 94/100 and a GF Value™ of $36.19 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Chemical Works of Gedeon Richter ranks better than 97.09% on this metric.

Chemical Works of Gedeon Richter has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Chemical Works of Gedeon Richter has Narrow Moat: RGEDF has a strong narrow moat due to its established brand, extensive distribution network, and valuable patents in the pharmaceutical industry. However, it faces competition from larger global players, limiting its moat to narrow.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Chemical Works of Gedeon Richter might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Chemical Works of Gedeon Richter  (OTCPK:RGEDF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Chemical Works of Gedeon Richter Moat Score Related Terms

RGEDF vs ZTS, UTHR, VTRS: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Chemical Works of Gedeon Richter's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chemical Works of Gedeon Richter Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chemical Works of Gedeon Richter's Moat Score distribution charts can be found below:

* The bar in red indicates where Chemical Works of Gedeon Richter's Moat Score falls into.


RGEDF
94GF Score
Chemical Works of Gedeon Richter PLC RGEDF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Chemical Works of Gedeon Richter (RGEDF) has a Moat Score of 6 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Chemical Works of Gedeon Richter ranks #30 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Chemical Works of Gedeon Richter's Moat Score too high?
Chemical Works of Gedeon Richter's current Moat Score is 6. Based on the distribution chart, Chemical Works of Gedeon Richter ranks #30 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Chemical Works of Gedeon Richter has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chemical Works of Gedeon Richter's Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Chemical Works of Gedeon Richter ranks #30 out of 1030 companies for Moat Score. This places Chemical Works of Gedeon Richter in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Chemical Works of Gedeon Richter's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemical Works of Gedeon Richter stock overvalued right now?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter (RGEDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $36.19, compared to a current price of $39.59 — trading 9.4% above its estimated fair value. The current Moat Score is 6. Chemical Works of Gedeon Richter's overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Chemical Works of Gedeon Richter (RGEDF), the current Moat Score is 6 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chemical Works of Gedeon Richter (RGEDF) Overvalued in 2026?

Based on GuruFocus' analysis, Chemical Works of Gedeon Richter stock appears to be overvalued. The current stock price of $39.59 is trading 9.4% above its estimated GF Value™ of $36.19. GuruFocus considers Chemical Works of Gedeon Richter to be Modestly Overvalued.

Key valuation signals for RGEDF:

  • Moat Score: 6
  • GF Value™: $36.19 vs. price of $39.59 (9.4% above fair value)
  • GF Score™: 94/100 with 5 warning signs

No single metric tells the full story. See the RGEDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chemical Works of Gedeon Richter Business Description

Address Gyomroi ut 19-21, Budapest, HUN, 1103
Chemical Works of Gedeon Richter PLC is a pharmaceutical company. The company focuses on the development and manufacture of gynaecological, cardiovascular, and central nervous system products. It manufactures medicines including original, generic and licensed products for treatment in the therapeutic area. The group is active in two business segments namely, the Pharma segment comprising Women's Healthcare, Neuropsychiatry, Biotechnology, General Medicine, and Other pharma; and the Others segment includes the remaining wholesale and retail business of the Group and all other activities. The company operates internationally.
94GF Score

Get the complete analysis for RGEDF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$39.59
Price
$36.19
GF Value